Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

Savara (NASDAQ:SVRA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Savara Stock Down 0.6%

Shares of Savara stock opened at $4.78 on Friday. Savara has a 12-month low of $3.34 and a 12-month high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The stock has a 50 day moving average price of $5.36 and a two-hundred day moving average price of $5.42. The stock has a market capitalization of $982.10 million, a P/E ratio of -8.24 and a beta of 0.20.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Equities analysts expect that Savara will post -0.61 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Savara during the 2nd quarter worth approximately $76,966,000. Polar Capital Holdings Plc acquired a new position in shares of Savara in the fourth quarter valued at $50,086,000. Nantahala Capital Management LLC acquired a new position in shares of Savara in the second quarter valued at $42,977,150. Spruce Street Capital LP bought a new position in Savara in the second quarter worth $21,267,868. Finally, Pictet Asset Management Holding SA bought a new position in Savara in the first quarter worth $12,424,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.